Mirum Pharmaceuticals (MIRM) Stock
Commercial pharmaceutical company for rare liver disease. Here's the price, business snapshot, and what's worth knowing about Mirum Pharmaceuticals in August 2026.
Mirum Pharmaceuticals (MIRM) is a clinical-stage to commercial biopharmaceutical company focused on liver diseases, particularly rare cholestatic conditions. Its research and development efforts centre on modifying bile acid pathways to address symptoms and disease progression in small patient populations. Investors should note Mirum’s growth profile hinges on successful regulatory milestones, commercialisation of its lead therapies, and the company’s ability to expand into additional indications or geographies. Like many biotech stocks, Mirum can show above-average volatility: clinical trial outcomes, reimbursement decisions and competitive developments can materially affect the share price. The company’s market capitalisation of about $3.47bn reflects investor expectations for future revenue and pipeline potential, but those expectations are uncertain. This summary is for general educational purposes only and not personalised financial advice; suitability depends on an investor’s goals, time horizon and risk tolerance.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Mirum Pharmaceuticals' stock with a target price of $105.74, indicating growth potential.
Financial Health
Mirum Pharmaceuticals is performing well with strong revenue and cash flow, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Rare‑disease focus
Concentrating on small, high‑need patient groups can mean regulatory incentives and premium pricing, though market size may limit revenue upside.
Regulatory catalysts
Milestones such as approvals or label expansions can move the stock; clinical setbacks can have the opposite effect, so outcomes are binary and impactful.
Commercial execution
Scaling sales, securing reimbursement and manufacturing reliably are essential to translate approvals into sustainable revenue; execution risks remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
